Actavis wins Lialda generic appeal

02-04-2014

The US Court of Appeals for the Federal Circuit has reversed a lower court decision that found Actavis’s generic version of Shire’s ulcerative colitis drug Lialda (mesalamine) infringes US patent 6,773,720.


Actavis, Shire, Lialda, generic, US Court of Appeals for the Federal Circuit

LSIPR